Zevra Therapeutics reported a negative CHMP ruling on arimoclomol for Niemann-Pick disease type C in the EU and said it will request a re-examination. The company will continue to support access through its Expanded Access Program and cites favorable real-world data and updated guidelines. Near-term sentiment could weaken on regulatory setback, while the re-examination process offers a potential pathway to EU approval.
Summary: - ZVRA reported a quarterly loss of $0.40 per share, beating estimates by 18.37%. - Revenues for ZVRA were $3.43 million, missing estimates by 2.70%. - ZVRA shares have decreased by 21% this year compared to the S&P 500. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
